Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
Hepatic EncephalopathyCirrhosis1 moreIndividuals with cirrhosis are likely to develop overt hepatic encephalopathy for which diagnostic modalities and treatment options are limited. The purpose of this study is to determine if individuals with cirrhosis who experience hepatic encephalopathy would benefit from investigational microbiota restoration therapy due to their inherent cognitive alterations. Analysis for a correlation between changes in microbiome composition and specific blood biomarkers could allow for earlier diagnosis of HE which could then be treated earlier and with novel treatments.
Rifamycin in Minimal Hepatic Encephalopathy
Hepatic EncephalopathyCirrhosis1 moreThis is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
Minimal Hepatic EncephalopathyThis research proposes to find whether the probiotic lactobacillus GG is safe and well tolerated in patients with minimal hepatic encephalopathy. We also want to get insight into the mechanisms of action of LGG.
AST-120 Used to Treat Mild Hepatic Encephalopathy
Mild Hepatic EncephalopathyThe purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
Effect of Yogurt on Minimal Hepatic Encephalopathy
CirrhosisMinimal Hepatic EncephalopathyThe purpose of this study is to determine whether a special yogurt can improve performance on certain tests of intelligence and decrease liver inflammation in patients with cirrhosis.
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life
Minimal Hepatic EncephalopathyHepatic EncephalopathyMinimal hepatic encephalopathy (MHE) has a negative effect on patients' daily functioning. No study has so far investigated the effect of treatment related improvement in cognitive functions on health related quality-of-life (HRQOL). This study was carried out to determine the influence of treatment on psychomotor performance and on HRQOL in patients with MHE. The mean number of abnormal NP tests decreased significantly in patients in treated group compared with patients in untreated group MANOVA for time and treatment, P =.001). Mean total SIP score improved among patients in the treated group after 3 months compared with patients in untreated group after 3 months (MANOVA for time and treatment, P=.002). Improvement in HRQOL was related to the improvement in psychometry. In conclusion, treatment with lactulose improves both cognitive functions and HRQOL in cirrhotic patients with MHE.
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy...
CirrhosisHepatic EncephalopathyThis is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
Hepatic EncephalopathyThe purpose of this study is to determine whether the administration of albumin in addition to the standard care is effective in the treatment of an episode of hepatic encephalopathy in patients with cirrhosis.
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)...
Hepatic CirrhosisHepatic Encephalopathy (HE)The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
Covert Hepatic EncephalopathySeveral studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.